alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2016191EN.01002101.xml

| 30.5.2016 | EN | Official Journal of the European Union | C 191/21 |
| --- | --- | --- | --- |

30.5.2016

EN

Official Journal of the European Union

C 191/21

---

Request for a preliminary ruling from the Conseil d'État (Belgium) lodged on 31 March 2016 — Sadikou Gnandi v État belge

(Case C-181/16)

(2016/C 191/26)

Language of the case: French

Referring court

Referring court

Conseil d'État

Parties to the main proceedings

Parties to the main proceedings

Appellant: Sadikou Gnandi

Appellant:

Respondent: État belge

Respondent:

Question referred

Question referred

Must Article 5 of Directive 2008/115/EC of the European Parliament and of the Council of 16 December 2008 on common standards and procedures in Member States for returning illegally staying third-country nationals, (1) which requires Member States to respect the principle of non-refoulement when they are implementing that directive, and the right to an effective remedy provided for under Article 13(1) of that directive and under Article 47 of the Charter of Fundamental Rights of the European Union, be interpreted as precluding the adoption of a return decision, as provided for under Article 6 of the aforementioned Directive 2008/115/EC and under Article 52/3(1) of the Law of 15 December 1980 on entry to the national territory, settlement, residence and removal of foreign nationals and Article 75(2) of the Royal Decree of 8 October 1981 on entry to the national territory, residence, settlement and removal of foreign nationals, after the rejection of the asylum application by the Commissioner General for Refugees and Stateless Persons and therefore before the legal remedies available against that rejection decision can be exhausted and before the asylum procedure can be definitively concluded?

1

---

(1)  OJ 2008 L 348, p. 98.

1

---
# C_2016383EN.01000202.xml

| 17.10.2016 | EN | Official Journal of the European Union | C 383/2 |
| --- | --- | --- | --- |

17.10.2016

EN

Official Journal of the European Union

C 383/2

---

Request for a preliminary ruling from the Naczelny Sąd Administracyjny (Poland) lodged on 19 July 2016 — Soufiane El Hassani v Minister Spraw Zagranicznych

(Case C-403/16)

(2016/C 383/03)

Language of the case: Polish

Referring court

Referring court

Naczelny Sąd Administracyjny

Parties to the main proceedings

Parties to the main proceedings

Appellant: Soufiane El Hassani

Appellant:

Respondent: Minister Spraw Zagranicznych

Respondent:

Question referred

Question referred

Must Article 32(3) of Regulation (EC) No 810/2009 of the European Parliament and of the Council of 13 July 2009 establishing a Community Code on Visas (Visa Code), (1) having regard to recital 29 of the Visa Code and the first paragraph of Article 47 of the Charter of Fundamental Rights of the European Union, be interpreted as requiring the Member States to guarantee an effective remedy (appeal) before a court of law?

1

---

(1)  OJ 2009 L 243, p. 1.

1

---
# C_2016454EN.01001901.xml

| 5.12.2016 | EN | Official Journal of the European Union | C 454/19 |
| --- | --- | --- | --- |

5.12.2016

EN

Official Journal of the European Union

C 454/19

---

Request for a preliminary ruling from the Tribunal da Relação de Évora (Portugal) lodged on 23 September 2016 — Luis Isidro Delgado Mendes v Crédito Agrícola Seguros — Companhia de Seguros de Ramos Reais, SA

(Case C-503/16)

(2016/C 454/33)

Language of the case: Portuguese

Referring court

Tribunal da Relação de Évora

Parties to the main proceedings

Applicant: Luis Isidro Delgado Mendes

Defendant: Crédito Agrícola Seguros — Companhia de Seguros de Ramos Reais, SA

Question referred

In the case of a road traffic accident resulting in personal injury and damage to property of a pedestrian who was intentionally run over by a motor vehicle of which he is the owner, which was being driven by the person who stole the car, does EU law, specifically Articles 12(3) and 13(1) of Directive 2009/103/EC (1) of the European Parliament and of the Council [of 16 September 2009 relating to insurance against civil liability in respect of the use of motor vehicles, and the enforcement of the obligation to insure against such liability] preclude the exclusion by national law of any form of compensation for the pedestrian in question as a result of the fact that he is the owner of the vehicle and the insurance policyholder thereof?

---

(1)  Directive 2009/103/EC of the European Parliament and of the Council of 16 September 2009 relating to insurance against civil liability in respect of the use of motor vehicles, and the enforcement of the obligation to insure against such liability (OJ 2009 L 263, p. 11).

---
Exhibit 10.56





March 1, 2007



Dr. Arthur J. Sytkowski

203 Park Avenue

Arlington, MA 02476



Dear Dr. Sytkowski,



This letter is to document our agreement that DNAPrint Genomics, Inc. (DNAPrint) will pay for unpaid invoices incurred to date and in the future, related to the Consulting Services Agreement dated August 1, 2006 (Consulting Agreement), in registered common stock.  We agree that you will be issued up to 30,000,000 shares of DNAPrint Genomics, Inc. common stock, that are registered on a Form S-8, as consideration for consulting services performed for DNAPrint in accordance with the Consulting Agreement.   Notwithstanding the foregoing, DNAPrint has the option to pay such amounts due to you in cash.  In addition, DNAPrint shall pay 5% interest on any amounts which remain unpaid for 30 days from the date payment is due to the date of stock issuance or cash payment.



Within thirty days of payment coming due under the Consulting Agreement, DNAPrint shall pay amounts due in cash or issue shares based upon the following calculation:



The average low price is computed by averaging the low price of the DNAPrint common stock for three days prior to the invoice date per the http://integratir.com/ site. This average low price will be discounted by 15% to determine the conversion price.  The invoice amount will be divided by the conversion price to equal the number of shares to issue.  Here is an example using a $1,000 invoice.



$0.010 low price 5th day before invoice

$0.009 low price 4th day before invoice

$0.011 low price 3rd day before invoice







|                                                                                                                                                             
|-------------------------------------------------------------------------------------------------------------------------------------------------------------
|$0.010 Average low price for three days prior to invoice date
15% Discount on price for fees
$0.0085 conversion price
$1,000 amount owed
Shares owed: 117,647





With fifteen days notice, Dr. Sytkowski and/or DNAPrint can cancel this agreement and require all payments owed to Dr. Sytkowski to be made in cash.





---

If you have any questions regarding the foregoing, please do not hesitate to contact me.  Please review, date and sign a copy of this letter agreement and return it to me as soon as possible.



Very truly yours,



|                                      |  |              
|------------------------------------- |  | -------------
|/s/ Richard Gabriel                   |  | 12 March 2007
|Richard Gabriel                       |  | Date         
|President and Chief Executive Officer |  |              



Accepted and Agreed



|                        |  |             
|----------------------- |  | ------------
|/s/ Arthur J. Sytkowski |  | 5 March 2007
|Dr. Arthur J. Sytkowski |  | Date        
|                        |  |
IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF PENNSYLVANIA

VIRGIL EMERSON and

LINDA EMERSON

:

:

: CIVIL ACTION NO. 02-CV-4290

Plaintiffs, :

:

v. :

:

BAYER CORPORATION;

BAYER AG;

GLAXOSMITHKLINE, PLC;

GLAXOSMITHKLINE;

SMITHKLINE BEECHAM

:

:

:

:

:

ENTRY OF APPEARANCE

:

Defendants. :

ENTRY OF APPEARANCE

To the Clerk of the Court:

Kindly enter the appearances of Hope S. Freiwald, Aline Fairweather, Erin

Brennan and Kirstin J. Miller as attorneys for defendant GlaxoSmithKline PLC.

Respectfully Submitted,

_____________________________ _____________________________

Hope S. Freiwald Aline Fairweather

_____________________________ _____________________________

Erin Brennan Kirstin J. Miller

DECHERT PRICE & RHOADS

4000 Bell Atlantic Tower

1717 Arch Street

Philadelphia, PA 19103-2793

(215) 994-4000

Case 2:02-cv-04290-CN Document 7 Filed 09/11/2002 Page 1 of 1
Quick Reference Contact Guide

Do you have a question about OTCnet?

If so, Fiscal Service is here to help. Contact one of our specialized OTCnet

teams available to assist you with your particular need.

Deployment Team

Assists each agency in the OTCnet conversion process and in the creation or 

expansion of new endpointsfor both deposit processing and check capture.

• Telephone: (703) 377-5586

• Email: FiscalService.OTCDeployment@citi.com

 

Security Team

Responsible for setting up all new PLSAs, initial authorizing of LSAs, and assisting 

agencies with the provisioning of new users.

• Telephone: (866) 945-7920, option 5

• Email: FiscalService.OTCSecurity@citi.com

Customer Support Team

Provides 24/7 technical assistance for locationsthat have been converted or onboarded to

the OTCnetsystem.

• Telephone: (866) 945-7920, option 2

• Email: FiscalService.OTCChannel@citi.com

For additional information, visit the OTCnet website at

https://www.fiscal.treasury.gov/fsservices/gov/rvnColl/otcnet/rvnColl_otcnet.htm
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 02702

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2File Name3

Description

02702\02702_Certification Statement.pdf Plant certification statement

x 02702\02702_Checklist.xls EPA Technical Review Checklist Workbook

02702\02702_Completeness_Checklist.xls EPA Completeness Review Checklist

x 02702\02702_PartA.xls Plant submitted survey file

x 02702\02702_PartB.xls Plant submitted survey file

x 02702\02702_PartC.xls Plant submitted survey file

x 02702\02702_PartD.xls Plant submitted survey file

x 02702\02702_PartH.xls Plant submitted survey file

x 02702\Supporting Documentation\02702_Part_A-1_GGS_Map-1.pdf Plant submitted supplemental files to the survey

x 02702\Supporting Documentation\02702_Part_A-2_GGS_Water_Balance_ Diagram.pdf Plant submitted supplemental files to the survey

x 02702\Supporting Documentation\02702_Part_C-1_Map-2.pdf Plant submitted supplemental files to the survey

x 02702\Supporting Documentation\02702_Part_D-1_GGS_ Pond_System_ Diagram.pdf Plant submitted supplemental files to the survey

x 02702\Supporting Documentation\PDF of Part\02702_Part_A-0_Final_GGS.pdf Plant submitted survey file

x 02702\Supporting Documentation\PDF of Part\02702_Part_B_Final_GGS.pdf Plant submitted survey file

x 02702\Supporting Documentation\PDF of Part\02702_Part_C-0_Final_GGS.pdf Plant submitted survey file

x 02702\Supporting Documentation\PDF of Part\02702_Part_D-0_Final_GGS.pdf Plant submitted survey file

x 02702\Supporting Documentation\PDF of Part\02702_Part_H_Final_GGS.pdf Plant submitted survey file

2

 Copyright documents are available from the docket. 

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

3

 No hardcopy log is included for this plant as no hardcopy materials were received.
<PAGE>

                                  EXHIBIT 23

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference into the Registration
Statement on Form S-8 for the Company's 1996 Stock Option Plan and 1996
Recognition and Retention Plan (Registration No. 333-83198) of our report dated
March 28, 2008 relating to the consolidated financial statements of First
Federal of Northern Michigan Bancorp, Inc. as of December 31, 2007 which appear
in this Form 10-KSB of First Federal of Northern Michigan Bancorp, Inc. for the
year ended December 31, 2007.

Plante & Moran, PLLC

Auburn Hills, Michigan
March 28, 2008
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 13

- 20207 Summary Calendar

UNITED STATES OF AMERICA,
Plaintiff

- Appellee

v. EMILIO DE LA GARZA

- MO NTEMAYOR, also known as Emilio D el La Garza

Montemayor, also known as Emilio DeLaGarza, also known as Emilio Montemayor DeLaGarza, also known as Emilio DeLaGarza

- Montemayor, also known as Emmillio DeLaGarza, also known as Emmi ll o De La Garza , Defendant

- Appellant

Appeal s from the United States District Court for the Southern District of Texas USDC No. 4:12

- CR

- 418

- 1

Before KING, DAVIS, and ELROD, Circuit Judges. PER CURIAM: * The attorney appointed to represent Emilio De La Garza

- Montemayor has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F .3d 229 (5th Cir. 2011). De La Garza

- Montemayor has filed a response. We have

* Pursuant to 5 TH C IR

. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED April 14, 2014 Lyle W. Cayce Clerk Case: 13-20207 Document: 00512594586 Page: 1 Date Filed: 04/14/2014No. 13

- 20207 reviewed counsel’s brief and the relevant portions of the record reflected therein , as well as De La Garza

- Montemayor ’ s response . We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. In his response, De La Garza

- Montemayor contends , inter alia, that his below

- range sentence should not be entitled to a presumpti on of reasonableness because his guideline sentencing range was ca lculated under U.S.S.G. § 2L1.2, which he argues is not based on empirical evidence. That contention is foreclosed, see United States v. Duarte , 569 F.3d 528, 529

- 31 (5th Cir. 2009), but by raising the argument De La Garza

- Montemayor has preserved it for further review. Accordingly, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. See 5 TH C IR

. R. 42.2.

2 Case: 13-20207 Document: 00512594586 Page: 2 Date Filed: 04/14/2014
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 1 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 2 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 3 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 4 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 5 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 6 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 7 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 8 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 9 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 10 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 11 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 12 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 13 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 14 of 15
Case 2:04-cv-03747-MMB Document 1 Filed 08/06/04 Page 15 of 15
Exhibit 23



            CONSENT OF INDEPENDENT REGISTERERD PUBLIC ACCOUNTING FIRM



The Board of Directors
GrandSouth Bancorporation

We consent to the  incorporation by reference to the  Registration  Statement of
GrandSouth  Bancorporation on Form S-8 relating to the GrandSouth Bancorporation
1998 Stock  Option  Plan (File no.  333-129580),  of our report  dated March 28,
2008, relating to the consolidated  balance sheets of GrandSouth  Bancorporation
and Subsidiary as of December 31, 2007, and the related consolidated  statements
of income,  changes in shareholders'  equity and comprehensive  income, and cash
flows for the year then ended,  which  appears in the Annual Report on Form 10-K
of GrandSouth Bancorporation for the year ended December 31, 2007.


                                     s/ Elliott Davis, LLC

Greenville, South Carolina
March 28, 2008
[Federal Register Volume 88, Number 204 (Tuesday, October 24, 2023)]
[Notices]
[Page 73020]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-23458]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to 5 U.S.C section 1009(d), notice is hereby given of the 
following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended, and the Determination of the Director, Office of 
Strategic Business Initiatives, Office of the Chief Operating Officer, 
CDC, pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--CE24-034, Rigorous Evaluation of 
Policies for their Impacts on the Primary Prevention of Multiple Forms 
of Violence.
    Date: February 27, 2024.
    Time: 8 a.m.-5 p.m., EST.
    Place: Web Conference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Carlisha Gentles, PharmD, BCPS, 
CDCES, Scientific Review Officer, National Center for Injury Prevention 
and Control, CDC, 4770 Buford Highway NE, Mailstop F-63, Atlanta, 
Georgia 30341, Telephone: (770)488-1504; Email: <a href="/cdn-cgi/l/email-protection#5b181c3e352f373e281b383f38753c342d"><span class="__cf_email__" data-cfemail="efaca88a819b838a9caf8c8b8cc1888099">[email protected]</span></a>.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-23458 Filed 10-23-23; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
SAT Report

PMN Number: P-12-0169

SAT Date: 2/7/2012

Print Date: 4/27/2015

Related cases: Yes

Health related cases: 

Ecotox related cases: 

Concern levels:

Type of Concern: Health Eco Comments

Level of Concern: 1 1 Health: PMN ; Eco: intact material

2 3 Health: DegPdt ; Eco: high concern for toxicity of incomplete incineration

products to terrestrial organisms

 Persistence Bioaccum Toxicity Comments

3 1 1 PMN

3 2 2 Deg Pdt

Exposure Based Review:

Health: No

Ecotox: No

Routes of exposure: Health: Dermal Drinking Water Inhalation Low Concern

Ecotox: No releases to water

Fate: ; PMN slow; Deg Pdt rapid

P2Rec Comments:

Comment: No Comment

Keywords:

 Keywords: 

NO SIG HLTH CNCRNS

PerFHxA:

LIVER

BLOOD

MALE REPRO

PFOA/PFOS:
 IMMUNO

 ONCO

Summary of Assessment:

 Fate:

Fate Summary: P-12-0169

FATE: MW = 2320 with 2.2% < 500 and 8.7% < 1000

Liquid with MP < 25 C (E)

S = Negl.

VP < 1.0E-6 torr at 25 C (E)

BP > 400 C (E)

H < 1.00E-8 (E)

POTW removal (%) = 90 via sorption

Time for complete ultimate aerobic biodeg > mo

Sorption to soils/sediments = PMN strong; Deg Pdt low

PBT Potential: PMN P3B1; Deg Pdt P3B2

*CEB FATE: Migration to ground water = PMN slow; Deg Pdt rapid

 Health:

 Health Summary: Absorption of the low molecular weight fraction (8.7% < 

1000, 2.2% < 500) is poor all routes, based on physical/chemical properties. No significant 

health concerns.

 For the potential incomplete incineration product, based on test data for the analogue 

perfluorohexanoic acid, concerns are liver toxicity, blood toxicity, and male reproductive 

toxicity [rat 28-day oral NOAEL = 50 mg/kg, LOAEL = 150 mg/kg with liver toxicity; rat 

90-day oral LOAEL = 10 mg/kg based on decreased body weight in males at all doses and liver 

toxicity and anemia at 200 mg/kg; there were toxic effects on the testes in 2 males in the 90-day 

oral study that were judged by the reviewer to be indicative of the potential for male

reproductive toxicity. There is also concern for immunosuppression and oncogenicity based on 

data for PFOA and PFOS.

 Ecotox:

Test Organism Test 

Type

Test End 

Point

Predicted Measured Comments

fish 96-h LC50 *

daphnid 48-h LC50 *

green algal 96-h EC50 *

fish _ chronic value *

daphnid _ chronic 

value

*

algal _ chronic 

value

*
Sewage Sludge 3-h EC50 _

Sewage Sludge _ Chronic 

Value

_

Ecotox Values Comments: Predictions are based on SARs for anionic polymers; SAR 

chemical class = polymer-anionic-(meth)acrylate-perFC6; MW 5470 with 8.7% < 1000 and 

2.2% < 500; liquid with mp unknown (P); S < 0.001 mg/L at 20 C(P); pH7; effective 

concentrations based on 100% active ingredients and mean measured concentrations; hardness 

<150.0 mg/L as CaCO3; and TOC <2.0 mg/L;

Factors Values Comments

Assessment Factor 10

Concentration of Concern 

(ppb)

*

SARs polyanionic polymers

SAR Class polymer-anionic-COO-perfluoro

C6

Ecotox Category Polyanionic Polymers (& 

Monomers)

Ecotox Factors Comments: 

 SAT Chair:
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bayou City Exploration, Inc. (the
"Company") on Form 10-QSB for the period ended March 31, 2006 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Morris
T. Hewitt, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of my knowledge:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.


/s/ Morris T. Hewitt
------------------------------------
Morris T. Hewitt
President and Chief Executive Officer

May 15, 2006
IPAC Monthly Operational Metrics - November 2016